You are here

In The News

Click here to read the entire press release.
Click here to read the announcement from Kedrion Biopharma regarding BIVIGAM.
The deadline to apply for IDF's Research Grant has been extended to February 22, 2017. This seed grant program was created to encourage and support patient oriented research on Primary Immunodeficiency Diseases, and is open to applicants currently based in the U.S. The program will consist of one-...
Last month, the outgoing administration decided to drop its controversial proposed Medicare Part B Drug Payment Model proposed by the Centers for Medicare and Medicaid Services (CMS) that would reduce payments to providers for Part B drugs like immunoglobulin (Ig) and impose more cost shifting...
By Marcia Boyle, IDF President & Founder Since the election, many people and organizations, including the Immune Deficiency Foundation, are focused on what will happen with healthcare coverage and access. There are many unknowns at this time, but we want to reassure members of the primary...
Starting September 12, 2016, eligible patients through the Hizentra Co-Pay Relief Program can receive up to $5,000 per year with no monthly cap to cover out-of-pocket expenses. Click here for the announcement.
Click here to read the press release about a new subcutaneous immunoglobulin (Ig) product: Shire announces U.S. FDA approval of CUVITRU™ [immune globulin subcutaneous (human), 20% solution] treatment for primary immunodeficiency.
Click here to read the updated statement from the Plasma Protein Therapeutics Association (PPTA).
Click here to read the press release from the Plasma Protein Therapeutics Association (PPTA).
Click here to read the press release.
Click here to read a story on EverydayHealth.com about coping with primary immunodeficiency disease.